SynCardia to Honor Eight Leading Total Artificial Heart Hospitals during ISHLT

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

This year’s awards recognize leadership in the Destination Therapy clinical trial, pioneering use of the 50cc Total Artificial Heart, outstanding outcomes, implant milestones and best launch

During the 37th annual meeting of the International Society for Heart & Lung Transplantation (ISHLT)* being held April 5-8 in San Diego, SynCardia Systems, LLC will honor the following eight hospitals for their lifesaving use of the SynCardia temporary Total Artificial Heart (TAH-t):

  • Destination Therapy Leader
    Virginia Commonwealth University (VCU) Medical Center
    Richmond, VA
    VCU Medical Center is the leading investigational site in the FDA-approved Investigational Device Exemption clinical trial of the 70cc Total Artificial Heart for destination therapy.
  • Pioneer Award – U.S.
    Ann & Robert H. Lurie Children’s Hospital of Chicago
    Chicago, IL
    Jaheim Whigham, 11, became the smallest and youngest patient to receive the 50cc Total Artificial Heart in the U.S. when Lurie Children’s performed its first implant in December 2016.
  • Pioneer Award – International
    Royal Brompton & Harefield NHS Foundation Trust
    London, United Kingdom
    Thanks to extraordinary cooperation between these two institutions, the smallest patient to receive the 50cc Total Artificial Heart in Europe was successfully bridged to transplant.
  • Outstanding Outcomes – U.S.
    University of Michigan Frankel Cardiovascular Center
    Ann Arbor, MI
    Eighty percent of patients who received the SynCardia Total Artificial Heart at Frankel Cardiovascular Center were bridged to transplant or are currently at home on support.
  • Outstanding Outcomes – International
    Montreal Heart Institute
    Quebec, Canada
    Eighty percent of patients who received the SynCardia Total Artificial Heart at Montreal Heart Institute were bridged to transplant.
  • Best Launch Award
    Tampa General Hospital (TGH)
    Tampa, FL
    TGH completed certification to implant the Total Artificial Heart in only 82 days and performed three implants during its first year as a SynCardia Certified Center.
  • Milestone Award – 175+ implants
    Heart and Diabetes Center NRW
    Bad Oeynhausen, Germany
  • Milestone Award – 100+ implants
    VCU Medical Center
    Richmond, VA
  • Milestone Award – 25 implants
    University of Washington Medical Center
    Seattle, WA

Attending ISHLT? Visit SynCardia at Booth 216 in the Harbor Ballroom at the Manchester Grand Hyatt San Diego.

*Awards are not part of the official ISHLT program

CAUTION – In the United States, the use of the SynCardia 70cc TAH-t for destination therapy is investigational.

CAUTION – In the United States, the SynCardia 50cc TAH-t is an investigational device, limited by federal law to investigational use.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.